Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Chemomab Therapeutics Ltd. (CMMB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.58-0.28 (-4.08%)
At close: 04:00PM EST
6.50 -0.08 (-1.22%)
After hours: 07:19PM EST
Advertisement

Chemomab Therapeutics Ltd.

Building 7
Kiryat Atidim
Tel Aviv 6158002
Israel
972 77 331 0156
https://www.chemomab.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Dale R. Pfost Ph.D.CEO & DirectorN/AN/A1957
Dr. Adi Mor George Ph.D.Co-Founder, Chief Scientific Officer & Exec. DirectorN/AN/A1982
Mr. Donald R. Marvin MBACFO, Exec. VP & COON/AN/A1953
Barbara LindheimConsulting VP of Investor & PR, Strategic CommunicationsN/AN/AN/A
Dr. Arnon Aharon M.D.Chief Medical OfficerN/AN/A1969
Dr. David M. Weiner M.D.Interim Chief Medical OfficerN/AN/A1965
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Corporate Governance

Chemomab Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement